ARCHIVES

FDA Committee IK IL-2/LAK For Modified Group C

This article is from The Cancer Letter archive.

Vol. 13 No. 18 | May 1, 1987

Download PDF Visit The Full Archive

Related Articles

Zeneca Buys 50% Stake In Salick, Gets Managed Care Access

January 6, 1995

Human Tissue Available Through NCI Network

July 10, 1987

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

December 31, 2010

NIH Reauthorization Compromise Between House and Senate Gives NCI Three Year Authorization Period

October 18, 1985

Neutron Clinical Trials Contract Concept Approved

June 22, 1984

In Brief: Waldmann, Fisher Win Top Miken Prizes Of $250,000 Each, Six Others Get $50,000

November 10, 1989